Back to Search
Start Over
Individual Comparison of Cholesterol Metabolism in Normal and Tumour Areas in Radical Prostatectomy Specimens from Patients with Prostate Cancer: Results of the CHOMECAP Study
- Source :
- European Urology Oncology, European Urology Oncology, Elsevier, 2019, 2 (2), pp.198-206. ⟨10.1016/j.euo.2018.08.001⟩, European Urology Oncology, 2019, 2 (2), pp.198-206. ⟨10.1016/j.euo.2018.08.001⟩
- Publication Year :
- 2019
- Publisher :
- Elsevier B.V., 2019.
-
Abstract
- International audience; BACKGROUND: Deregulation of cholesterol metabolism represents a hallmark of prostate cancer (PCa) and promotes its development. OBJECTIVE: To compare cholesterol metabolism on individual paired normal and tumour prostate tissues obtained from patients with PCa. DESIGN, SETTING, AND PARTICIPANTS: Between 2008 and 2012, normal and tumour paired tissue samples were collected from radical prostatectomy specimens from a cohort of 69 patients treated for localised PCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Tumour and normal tissues were subjected to gene analysis, sterol measurement, and immunohistochemistry. The Wilcoxon paired test and Spearman test were applied for comparison and correlation analyses, respectively. Principal component analysis was also carried out to investigate relationships between quantitative variables. RESULTS AND LIMITATIONS: Overall, cholesterol concentrations were not significantly different between tissue pairs. However, tumour samples were significantly associated with downregulated de novo cholesterol synthesis, but exhibited 54.7% overexpression of SCARB1 that could increase high-density lipoprotein uptake in PCa. Tumour tissues showed different trafficking of available cholesterol, with significantly lower ACAT1, and an altered efflux via APOE. Furthermore, cholesterol metabolism in tumour tissues was characterised by higher accumulation of 7alpha-hydroxycholesterol (OHC), 7betaOHC, and 7-ketosterol, and a lower level of 27OHC. CONCLUSIONS: Focusing on individually paired prostate tissues, our results highlighted several differences between normal and tumour samples linked to a metabolic shift in cholesterol flux. PCa samples exhibited a specific tissue signature characterised by higher SCARB1 expression, higher accumulation of OHC species, and clear downregulation of de novo cholesterol synthesis. PATIENT SUMMARY: Comparing normal and tumour tissues from the same prostates, our study identified a set of alterations in prostate cancer samples in terms of their use of cholesterol. These included higher cholesterol uptake, accumulation of oxidised cholesterol derivatives, and autonomous cellular production of cholesterol. Together, these data provide promising clinical targets to fight prostate cancer.
- Subjects :
- Apolipoprotein E
Male
[SDV]Life Sciences [q-bio]
030232 urology & nephrology
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
Prostate
Gene Regulatory Networks
Ester
Acetyl-CoA C-Acetyltransferase
Principal Component Analysis
Esters
Oxysterols
Middle Aged
Scavenger Receptors, Class B
3. Good health
Gene Expression Regulation, Neoplastic
Sterols
medicine.anatomical_structure
Cholesterol
Oncology
030220 oncology & carcinogenesis
Immunohistochemistry
lipids (amino acids, peptides, and proteins)
Sterol Regulatory Element Binding Protein 2
medicine.medical_specialty
Urology
[SDV.CAN]Life Sciences [q-bio]/Cancer
Deregulation
03 medical and health sciences
Apolipoproteins E
Oxysterol
Internal medicine
medicine
Humans
Radiology, Nuclear Medicine and imaging
Aged
Prostatectomy
[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health
business.industry
Gene Expression Profiling
Prostatic Neoplasms
[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology
medicine.disease
Sterol
SCARB1
Endocrinology
chemistry
Surgery
business
Lipoprotein
Subjects
Details
- Language :
- English
- ISSN :
- 25889311
- Database :
- OpenAIRE
- Journal :
- European Urology Oncology, European Urology Oncology, Elsevier, 2019, 2 (2), pp.198-206. ⟨10.1016/j.euo.2018.08.001⟩, European Urology Oncology, 2019, 2 (2), pp.198-206. ⟨10.1016/j.euo.2018.08.001⟩
- Accession number :
- edsair.doi.dedup.....33024b6465c8988fc4f14d1bf63f3ff1